KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Accumulated Expenses: 2009-2025

Historic Other Accumulated Expenses for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $8.9 million.

  • Rigel Pharmaceuticals' Other Accumulated Expenses fell 10.27% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year decrease of 10.27%. This contributed to the annual value of $10.4 million for FY2024, which is 94.90% up from last year.
  • Rigel Pharmaceuticals' Other Accumulated Expenses amounted to $8.9 million in Q3 2025, which was up 4.07% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Other Accumulated Expenses ranged from a high of $17.6 million in Q3 2022 and a low of $5.0 million during Q3 2023.
  • Its 3-year average for Other Accumulated Expenses is $7.1 million, with a median of $5.9 million in 2024.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 112.57% in 2021, then crashed by 71.42% in 2023.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Other Accumulated Expenses stood at $13.5 million in 2021, then crashed by 51.98% to $6.5 million in 2022, then decreased by 17.75% to $5.3 million in 2023, then spiked by 94.90% to $10.4 million in 2024, then decreased by 10.27% to $8.9 million in 2025.
  • Its Other Accumulated Expenses stands at $8.9 million for Q3 2025, versus $8.6 million for Q2 2025 and $7.4 million for Q1 2025.